Androgen-deprivation therapy is associated with Alzheimer's disease

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Androgen-deprivation therapy (ADT) in patients with prostate cancer is associated with the development of Alzheimer's disease.

Why this matters

  • Clinicians considering treating prostate cancer with ADT may also want to consider the patient's risk for Alzheimer's disease as well.

Key results

  • Patients were divided into 4 groups: non-ADT (patients who never received ADT; n=8401), patients who received injections for at least 3 mo (injection cohort [INJ]; n=1008), patients who received oral therapy for at least 3 mo (n=9963), and patients who received injections and oral medication (n=4905).
  • Non-ADT incidence of AD was 2.78/1000 person-years and 5.66/1000 in the ADT cohort.
  • Age-adjusted Cox proportional hazards regression model showed that the ADT cohort was 1.84 times more likely to develop dementia than the non-ADT group.

Study design

  • Retrospective analysis of data from 24,360 patients with prostate cancer who were and were not receiving ADT for 4 y and analyzed the relationship between ADT and the development of dementia.
  • Funding: None disclosed.

Limitations

  • Retrospective study design.
  • Non-ADT patients were generally younger than ADT patients.